



**Oliver Schnell**

**Kontakt**

Oliver Schnell

## Publikationen (12)

Goldberg J, Z'Graggen W, Hlavica M, Branca M, Marbacher S, D'Alonzo D, Fandino J, Stienen M, Neidert M, Burkhardt J, Regli L, Seule M, Roethlisberger M, Guzman R, Zumofen D, Maduri R, Daniel R, El Rahal A, Corniola M, Bijlenga P, Schaller K, Rölz R, Scheiwe C, Shah M, Heiland D, Schnell O, Beck J, Raabe A, Fung C. Quality of Life After Poor-Grade Aneurysmal Subarachnoid Hemorrhage. *Neurosurgery* 2023

Masalha W, Heiland D, Steiert C, Krüger M, Schnell D, Heiland P, Bissolo M, Grosu A, Schnell O, Beck J, Grauvogel J. Management of Medial Sphenoid Wing Meningioma Involving the Cavernous Sinus: A Single-Center Series of 105 Cases. *Cancers (Basel)* 2022; 14

Masalha W, Heiland D, Steiert C, Krueger M, Schnell D, Scheiwe C, Grosu A, Schnell O, Beck J, Grauvogel J. A Retrospective Evaluation of the Retrosigmoidal Approach for Petroclival Meningioma Surgery and Prognostic Factors Affecting Clinical Outcome. *Front Oncol* 2022; 12:786909.

Raabe A, Beck J, Goldberg J, Z Graggen W, Branca M, Marbacher S, D'Alonzo D, Fandino J, Stienen M, Neidert M, Burkhardt J, Regli L, Hlavica M, Seule M, Roethlisberger M, Guzman R, Zumofen D, Maduri R, Daniel R, El Rahal A, Corniola M, Bijlenga P, Schaller K, Rölz R, Scheiwe C, Shah M, Heiland D, Schnell O, Fung C. Herniation World Federation of Neurosurgical Societies Scale Improves Prediction of Outcome in Patients With Poor-Grade Aneurysmal Subarachnoid Hemorrhage. *Stroke* 2022; 53:2346-2351.

Masalha W, Beck J, Grosu A, Schnell O, Scheiwe C, Schnell D, Krüger M, Steiert C, Heiland D, Grauvogel J. Progression-Free Survival, Prognostic Factors, and Surgical Outcome of Spheno-Orbital Meningiomas. *Front Oncol* 2021; 11:672228.

Masalha W, Heiland D, Beck J, Schnell O, Krüger M, Delev D, Weber S, Pompe N, Woerner J, Daka K, Grauvogel J. Metabolic alterations in meningioma reflect the clinical course. *BMC cancer* 2021; 21:211.

Ravi V, Hofmann U, Schnell O, Beck J, Follo M, Delev D, Mader I, Shah M, Sankowski R, Meyer-Luehmann M, Franco P, Naseri Y, d'Errico P, Garrelfs N, Behringer S, Wurm J, Joseph K, Heiland D. Human organotypic brain slice culture: a novel framework for environmental research in neuro-oncology. *Life Sci Alliance* 2019; 2

Neurooncology Working Group of the German Cancer Society, Simon M, Tonn J, Stummer W, Schaub C, Weller J, Kebir S, Schäfer N, Stuplich M, Vatter H, Misch M, Keil V, Nelles M, Glas M, Coch C, Pietsch T, Hattingen E, Schmid M, Fimmers R, Weller M, Wick W, Coenen M, Urbach H, Vajkoczy P, Galldiks N, Bullinger L, Goldbrunner R, Grauer O, Krex D, Kortmann R, Hau P, Sabel M, Schlegel U, Steinbach J, Mack F, Tzaridis T, Schnell O, Bähr O, Renovanz M, Weyerbrock A, Brehmer S, Suchorska B, Schmidt-Graf F, Ringel F, Kowalski T, Tabatabai G, Seidel C, Uhl M, Herrlinger U. Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): a randomised, open-label, phase 3 trial. *Lancet* 2019; 393:678-688.

Schäfer N, Proescholdt M, Steinbach J, Weyerbrock A, Hau P, Grauer O, Goldbrunner R, Friedrich F, Rohde V, Ringel F, Schlegel U, Sabel M, Ronellenfitsch M, Uhl M, Grau S, Hänel M, Schnell O, Krex D, Vajkoczy P, Tabatabai G, Mack F, Schaub C, Tzaridis T, Nießen M, Kebir S, Leutgeb B, Urbach H, Belka C, Stummer W, Glas M, Herrlinger U. Quality of life in the GLARIUS trial randomizing bevacizumab/irinotecan versus temozolomide in newly diagnosed, MGMT-nonmethylated glioblastoma. *Neuro Oncol* 2018; 20:975-985.

Heiland D, Prinz M, Weyerbrock A, Carro M, Pfeifer D, Gäbelein A, Heynckes S, Masalha W, Mercas B, Delev D, Haaker G, Schnell O. Comprehensive analysis of PD-L1 expression in glioblastoma multiforme. *Oncotarget* 2017

Heiland D, Weyerbrock A, Urbach H, Staszewski O, Schnell O, Pfeifer D, Kiselev V, Kellner E, Demerath T, Mader I. Molecular differences between cerebral blood volume and vessel size in glioblastoma multiforme. *Oncotarget* 2016

Herrlinger U, Kortmann R, Mehdorn M, Tüttenberg J, Mayer-Steinacker R, Fietkau R, Brehmer S, Mack F, Stuplich M, Kebir S, Kohnen R, Dunkl E, Leutgeb B, Proescholdt M, Pietsch T, Urbach H, Belka C, Stummer W, Gerlach R, Vajkoczy P, Schäfer N, Steinbach J, Weyerbrock A, Hau P, Goldbrunner R, Friedrich F, Rohde V, Ringel F, Schlegel U, Sabel M, Ronellenfitsch M, Uhl M, Maciaczyk J, Grau S, Schnell O, Hänel M, Krex D, Glas M. Bevacizumab Plus Irinotecan Versus Temozolomide in Newly Diagnosed O6-Methylguanine-DNA Methyltransferase Nonmethylated Glioblastoma: The Randomized GLARIUS Trial. *J Clin Oncol* 2016; 34:1611-9.

## Projekte (0)

Keine Resultate gefunden.

---

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

[support.forschung@kssg.ch](mailto:support.forschung@kssg.ch)